How Long Do Kymriah CAR T Cells Persist in Patients?
Kymriah (tisagenlecleucel), a CD19-directed CAR T-cell therapy for certain blood cancers, shows variable persistence. In pediatric and young adult B-cell acute lymphoblastic leukemia (ALL) patients, CAR T cells often remain detectable for months to years. Clinical data from the ELIANA trial indicate persistence in 79% of patients at 3 months, 59% at 6 months, and 27% at 12 months post-infusion, with some lasting beyond 2 years.[1][2]
In adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), persistence is shorter: detectable in about 46% at 3 months and 19% at 6 months, per the JULIET trial.[1][3]
Factors Affecting Kymriah Persistence
Persistence depends on disease type, patient age, prior treatments, and tumor burden. Younger patients with ALL tend to have longer-lasting CAR T cells due to less prior immunosuppression. High disease burden or early relapse correlates with faster CAR T cell decline. Manufacturing uses patient-derived T cells expanded ex vivo, re-infused once, so persistence relies on in vivo expansion and survival without further dosing.[2][4]
What Happens as Kymriah Cells Decline Over Time?
Decline doesn't always mean treatment failure; many patients achieve remission before CAR T cells become undetectable, sustained by immune memory or B-cell aplasia (a marker of ongoing activity). Relapse often involves CD19-negative escape, not just loss of CAR T cells. Long-term monitoring shows B-cell aplasia persisting up to 4+ years in responders, even with low CAR T detection.[1][5]
Comparison to Other CAR T Therapies' Persistence
Kymriah's persistence is similar to Yescarta (axicabtagene ciloleucel), which lasts 3-12 months in lymphoma but fades faster in some. Tecartus shows prolonged presence in mantle cell lymphoma (up to years). Newer bispecifics or allogeneic CAR Ts aim for better durability but face rejection risks.[3][6]
Clinical Implications and Long-Term Data
Up to 5-year follow-up in ALL trials reports ongoing remissions in ~50% of patients with CAR T persistence beyond 1 year, though late relapses occur. No upper limit on persistence is defined; rare cases exceed 10 years in early trials. FDA labeling notes monitoring for at least 4 weeks post-infusion, with persistence tied to durable responses.[2][5]
[1]: Novartis. Kymriah (tisagenlecleucel) Prescribing Information. 2023. https://www.fda.gov/media/96799/download
[2]: Maude SL et al. N Engl J Med. 2018;378(5):439-448.
[3]: Schuster SJ et al. N Engl J Med. 2019;380(1):45-56.
[4]: Fraietta JA et al. Nature. 2018;554(7693):307-311.
[5]: Roddie C et al. Blood Adv. 2021;5(5):1350-1364.
[6]: Jacobson CA et al. Blood. 2022;139(19):2930-2942.